<DOC>
	<DOC>NCT01406717</DOC>
	<brief_summary>SPIL1033 resembles a gut hormone, which increases the insulin secretion, thus helps in reducing blood glucose levels. The purpose of study is to establish safety and efficacy of SPIL1033</brief_summary>
	<brief_title>Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>SPIL1033 is subcutaneous injection is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus. In this study, efficacy and safety of SPIL1033 will be evaluated. Subjects will receive SPIL1033 or placebo, 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male and female subjects 20 years of age and older. Established clinical diagnosis of type 2 diabetes mellitus treated with diet and exercise or antidiabetic agents as monotherapy or combination therapy. Weight stable: their weight should not have varied more than 10% of screening visit weight, within 6 months prior to screening visit. Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator(s); with a negative urine pregnancy test. Willing to participate and give written informed consent. Previous exposure to exenatide (antiexenatide antibodies at screening) or a GLP1 analogue. Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, rimonabant, or similar overthecounter medications) within 3 months of screening. Received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of trial entry. Severe renal impairment (creatinine clearance &lt;30 ml/min) or end stage renal disease.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SPIL1033</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>